Depressive Mood Tendency and Your Genetics

By the ExomeDNA Science Team

This page contains general information only. For personal health decisions, consult a qualified clinician.

Depressive Mood Tendency describes a person's genetically influenced baseline toward experiencing low mood, and is measured in the general population — not as a clinical label. Research drawing on data from nearly half a million individuals has identified common genetic variants that shift where a person sits on this spectrum. Below: what those genes do, what the evidence supports, and practical steps informed by the biology.

What is Depressive Mood Tendency?

Depressive Mood Tendency is a quantitative trait — a continuous, normally distributed characteristic in the general population — that captures how often a person experiences low, blue, or depressed mood. It is measured by questionnaire items such as "I have felt depressed" or "I have felt blue" administered to large cohorts, most prominently participants in the UK Biobank. This is not a label of major depressive disorder (MDD). It describes normal variation in mood experience: most people cluster near the middle of the spectrum, some rarely notice low moods, and some experience them frequently. Genetic factors account for a meaningful fraction of where any individual lands on this continuum. Because the trait spans the full population, the genes identified are relevant to a broad audience — not only those with clinical histories.

The genetics behind Depressive Mood Tendency

Four genes in your authorized result panel — ACVR2A, AGBL2, CAMTA1, and CCDC68 — have been associated with variation in depressed-affect scores through large-scale genome-wide analyses. Each points toward a distinct biological layer.

ACVR2A — the activin stress-resilience receptor

ACVR2A encodes Activin Receptor Type IIA, a cell-surface receptor for activin and related members of the TGF-beta superfamily. In the brain, activins are produced by neurons and glial cells and exert neuroprotective effects: activin signaling promotes neuronal survival, dendritic growth, and synaptic strengthening. The signaling cascade works as follows — activin binds ACVR2A, which then recruits and phosphorylates ACVR1B (also called ALK4), and that complex phosphorylates SMAD2 and SMAD3 proteins, which travel to the nucleus and switch on target gene programs. Animal research has shown that infusing activin directly into the hippocampus produces antidepressant-like behavioral effects. This means ACVR2A acts as an entry point for a molecularly defined stress-resilience pathway. Common variants in ACVR2A may alter the efficiency of this receptor, shifting how readily the brain can activate its own neuroprotective activin response under adversity. Lower receptor efficiency would reduce the amplitude of the protective response during stressful periods, increasing the likelihood of more frequent depressed mood.

CAMTA1 — the calcium-to-gene-expression bridge

CAMTA1 encodes Calmodulin-Binding Transcription Activator 1, a transcription factor with a unique calmodulin-binding domain (CaMBD). The mechanism is calcium-gated: when neuronal activity causes intracellular calcium to rise, calcium binds calmodulin, and calmodulin in turn binds and activates CAMTA1 — triggering expression of downstream target genes including BDNF (brain-derived neurotrophic factor) and other neuroprotective factors. This makes CAMTA1 a direct molecular bridge between neuronal activity and protective gene expression. Rare CAMTA1 mutations cause cerebellar ataxia and intellectual disability, confirming its essential brain function. Common variants likely shift the threshold at which the calcium signal activates CAMTA1's transcriptional program: a higher threshold means less protective gene expression during the same level of neuronal activity, reducing the brain's capacity for experience-dependent mood regulation. Importantly, aerobic exercise raises neuronal calcium, which is one mechanistic reason why exercise reliably boosts BDNF and supports mood.

AGBL2 — tubulin dynamics and dendritic spine health

AGBL2 encodes a metallocarboxypeptidase involved in post-translational modification of tubulin — specifically, it participates in the detyrosination of alpha-tubulin and related reactions that regulate microtubule dynamics. Microtubule stability is central to neuronal morphology, particularly the architecture of dendritic spines. Loss of dendritic spine density and complexity is one of the most replicated neurobiological findings in depression research: stress and chronic depressed states are associated with spine retraction, while antidepressant treatments partially reverse this. AGBL2 variants that alter tubulin-modification balance may therefore affect the structural plasticity of neurons in mood-relevant circuits, influencing baseline mood tendency through morphological rather than signaling mechanisms.

CCDC68 — an emerging signal

CCDC68 (Coiled-Coil Domain Containing 68) is expressed in the brain. Its precise contribution to the depressed-affect association signal has not yet been fully characterized in the published literature. Its inclusion here reflects its genome-wide significant association signal in the neuroticism and depressed-affect meta-analysis; mechanistic work is ongoing.

What the research says

Research base: Moderate. The association signal for depressive mood tendency draws on GWAS data at large scale but is inherently polygenic, and individual gene-to-mechanism causal evidence varies across loci.

The primary basis for this trait's genetic associations is the meta-analysis by Nagel and colleagues (2018, PMID 29942085), which pooled genome-wide association data across 449,484 individuals to study neuroticism — a broad personality dimension that encompasses depressed affect as a central component. The study reached genome-wide significance for multiple loci and identified biological pathways involving neuronal signaling, synaptic structure, and stress-response systems. Neuroticism and depressed affect are correlated but distinct constructs; the genes identified in neuroticism meta-analyses overlap substantially with those found in more targeted depressed-affect analyses, reflecting their shared biological architecture.

Key quantitative anchors from this evidence base:

• Sample size: 449,484 individuals in the Nagel 2018 meta-analysis (Nagel M, 2018)
• Genome-wide significance threshold: p < 5 x 10^-8 applied across loci
• The depressed-affect phenotype was measured using self-report questionnaire items in large population cohorts (primarily UK Biobank), capturing variation across the full distribution of mood experience

The moderate confidence tier reflects that while the sample sizes are large and the loci are genome-wide significant, the effect sizes of individual common variants are small (each explaining a fraction of a percent of trait variance), and for some genes (particularly CCDC68), the molecular mechanism linking the variant to the phenotype has not been fully resolved. As with all polygenic traits, the result represents a probabilistic tendency, not a deterministic outcome. Full methodology details are available at /methodology.

How Depressive Mood Tendency affects you

A higher genetic score on this trait means your genome, on average across these loci, patterns toward the portion of the population that reports more frequent low or depressed mood in questionnaire studies. This is a statistical tendency, not a ceiling on your experience. Several points matter for interpretation:

It is a spectrum, not a switch. The trait is continuous. There is no threshold at which "high" becomes "depressed" in a clinical sense. Many people with high genetic scores rarely experience notable low moods; many with low genetic scores do experience them — because environment, life events, social factors, and non-genetic biology all contribute substantially.

Biology shapes baseline, not destiny. The ACVR2A and CAMTA1 pathways are modifiable by behavior. Neuronal calcium activity, BDNF expression, and activin signaling are all responsive to lifestyle inputs. The genetic tendency describes a starting point for how efficiently these systems operate under default conditions — not how they must perform.

Subclinical mood tendency has real-world relevance. Even below the threshold of clinical depression, frequent low mood affects motivation, energy, sleep quality, relationship satisfaction, and cognitive performance. Understanding the biological substrate behind a mood tendency can motivate engagement with the lifestyle factors that specifically address those substrates.

The distinction from clinical assessment matters. This result is not a genetic risk score for major depressive disorder, though the two constructs share genetic architecture. A persistent, impairing depressive episode warrants clinical evaluation regardless of genetic profile.

Working with your Depressive Mood Tendency result

The biological mechanisms identified for this trait — activin/ACVR2A stress-resilience signaling, CAMTA1 calcium-driven gene expression, AGBL2 dendritic spine morphology — each have known behavioral and lifestyle correlates. The following are ordered by the strength of their connection to the underlying biology:

1. Aerobic exercise. Exercise raises neuronal intracellular calcium, which directly activates the CAMTA1 pathway and stimulates BDNF expression. Consistent aerobic activity (most guidelines suggest 150 minutes per week of moderate-intensity exercise) is the most well-supported behavioral intervention for BDNF-dependent mood regulation and has been shown in meta-analyses to reduce depressive symptoms comparably to antidepressant medication in mild-to-moderate presentations. For someone with CAMTA1 variants that raise the activation threshold, the argument for consistent aerobic exercise as a biological necessity — not a lifestyle add-on — is mechanistically grounded.

2. Consistent, sufficient sleep. Sleep is required for synaptic pruning and dendritic spine maintenance. Chronic sleep restriction accelerates spine loss in prefrontal circuits — the same morphological change implicated in the AGBL2 pathway. Protecting sleep duration and timing consistency directly addresses the dendritic-spine dimension of this trait's biology.

3. Stress management and recovery practices. Activin signaling (ACVR2A pathway) is most protective when the brain is not under sustained, unremitting stress loads. Practices that support parasympathetic recovery — structured relaxation, mindfulness-based approaches, or deliberate recovery periods — reduce chronic sympathetic activation and preserve the conditions under which activin-mediated neuroprotection can operate. Evidence for mindfulness-based stress reduction (MBSR) in reducing depressive relapse is substantial.

4. Social connection. Social engagement is one of the most robust non-pharmacological buffers against low mood and provides repeated neurobiological activations (oxytocin, dopamine, serotonin) that support the mood-regulating circuits identified in this trait's gene panel.

5. Omega-3 fatty acid adequacy. DHA and EPA, found in oily fish and concentrated supplements, support BDNF synthesis and neuronal membrane fluidity relevant to dendritic spine health. Population studies associate higher dietary omega-3 intake with lower rates of depressive symptoms.

6. Structured routine and behavioral activation. Particularly relevant for periods when low mood reduces motivation, structured scheduling of rewarding or meaningful activities (behavioral activation, a core CBT technique) counters the withdrawal cycles that amplify mood lows independent of genetic profile.

7. Professional evaluation when warranted. If depressed mood is persistent, frequent, or interfering with daily function, this trait result is not a substitute for professional clinical assessment. Effective treatments — psychotherapy, pharmacotherapy, or combined — exist and are not negated by genetic profile.

Related traits and genes

Depressive Mood Tendency sits within a cluster of traits sharing neurobiological architecture with mood regulation, stress response, and personality dimensions.

Sibling traits (same category):

• Neuroticism Tendency — overlapping genetic architecture; neuroticism is the broad personality dimension of which depressed affect is a primary component; shares GWAS loci with this trait
• Anxiety Tendency — stress-response and amygdala-reactivity genetics; ACVR2A activin signaling has relevance across mood and anxiety phenotypes
• Sleep Quality Tendency — disrupted sleep both causes and is caused by depressed affect; overlapping biology at the level of circadian rhythms and synaptic maintenance

Cross-category traits:

• Stress Cortisol Response — HPA-axis regulation and cortisol dynamics are upstream regulators of activin signaling and BDNF; chronic cortisol elevation suppresses both pathways implicated in this trait
• BDNF Activity — CAMTA1 drives BDNF expression; BDNF is the most studied molecular mediator of exercise-induced mood improvement and antidepressant action

Frequently asked questions

Does a high score mean I will develop depression?

No. This result reflects where your genome patterns on a continuous population spectrum of mood tendency. It does not predict a clinical outcome. Many people with high scores never develop depression, and many people with low scores do — because life events, social context, physical health, and many non-genetic factors contribute at least as much as genetics to whether any individual experiences a depressive episode.

Is this the same as a genetic test for major depressive disorder?

These are related but distinct. This trait measures "depressed affect" — how often you report feeling low or blue — as measured by questionnaire in the general population. Major depressive disorder is a clinical condition requiring specific symptom criteria, duration, and functional impairment. The genetic architectures overlap substantially, but this result is a quantitative wellness indicator, not a clinical label.

What does the ACVR2A gene actually do for mood?

ACVR2A is a receptor for activin, a signaling protein with neuroprotective and antidepressant-like effects in the brain. When activin binds ACVR2A, it triggers a molecular cascade (through SMAD proteins) that switches on protective gene programs in neurons. Animal research has shown that activin infused into the hippocampus produces antidepressant behavioral effects. Variants in ACVR2A may reduce how efficiently this protective response is activated during stress.

Can exercise really change how these genes affect me?

Aerobic exercise increases intracellular calcium in neurons, which activates the CAMTA1 pathway — directly driving expression of BDNF and other neuroprotective genes. The connection between exercise and the biology of this trait is not general wellness advice: it is mechanistically specific. Consistent aerobic exercise is the most evidence-supported behavioral tool for engaging the exact molecular pathways identified here.

Should I be concerned if I scored higher on this trait?

A higher score is information, not a verdict. Many people across the higher portion of this spectrum live without notable mood problems; many also find that understanding the biological basis of a mood tendency motivates them to engage more consistently with exercise, sleep, and stress management. If you are experiencing persistent or impairing low mood, a clinical evaluation is appropriate — and is not made unnecessary by any genetic result.

How confident is the science on these specific genes?

The research base is rated Moderate. The Nagel 2018 meta-analysis of 449,484 individuals identified these loci at genome-wide significance, which is a high statistical bar. However, individual variants explain a small fraction of trait variance, the effect sizes are modest, and for some genes (CCDC68) full mechanistic characterization is still ongoing. The science is solid at the population level; individual-level prediction from any polygenic trait remains probabilistic.

References

1. Nagel M, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. Nature Genetics. 2018. PMID 29942085.

Data sources: GWAS Catalog (https://www.ebi.ac.uk/gwas/); Open Targets Genetics (https://genetics.opentargets.org/); NCBI Gene (https://www.ncbi.nlm.nih.gov/gene/); ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/).

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.